Collaborations & Alliances

KBI Biopharma, Infinimmune Partner to Support Antibody Manufacturing

Will leverage KBI’s advanced monoclonal antibody development and manufacturing platform, SUREmAb, powered by Selexis.

KBI Biopharma, Inc., a JSR Life Sciences company and cGMP CDMO, and Infinimmune, Inc., a biotechnology company developing human-first antibody discovery and design, entered a collaboration to advance manufacturing of Infinimmune’s lead human monoclonal antibody (IFX-101) program. The first antibody in Infinimmune’s therapeutic drug development pipeline, IFX-101, targets atopic dermatitis and is designed to deliver superior efficacy with extended dosing intervals. By sourcing antibodies direct...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters